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Preliminary evidence of increased striatal
dopamine in a nonhuman primate model
of maternal immune activation
Melissa D. Bauman1,2,3, Tyler A. Lesh1, Douglas J. Rowland4, Cynthia M. Schumann1,3, Jason Smucny1, David L. Kukis4,
Simon R. Cherry4,5, A. Kimberley McAllister6 and Cameron S. Carter1
Abstract
Women exposed to a variety of viral and bacterial infections during pregnancy have an increased risk of giving birth to
a child with autism, schizophrenia or other neurodevelopmental disorders. Preclinical maternal immune activation
(MIA) models are powerful translational tools to investigate mechanisms underlying epidemiological links between
infection during pregnancy and offspring neurodevelopmental disorders. Our previous studies documenting the
emergence of aberrant behavior in rhesus monkey offspring born to MIA-treated dams extends the rodent MIA model
into a species more closely related to humans. Here we present novel neuroimaging data from these animals to
further explore the translational potential of the nonhuman primate MIA model. Nine male MIA-treated offspring and
4 controls from our original cohort underwent in vivo positron emission tomography (PET) scanning at approximately
3.5-years of age using [18F] fluoro-l-m-tyrosine (FMT) to measure presynaptic dopamine levels in the striatum, which
are consistently elevated in individuals with schizophrenia. Analysis of [18F]FMT signal in the striatum of these
nonhuman primates showed that MIA animals had significantly higher [18F]FMT index of influx compared to control
animals. In spite of the modest sample size, this group difference reflects a large effect size (Cohen’s d= 0.998).
Nonhuman primates born to MIA-treated dams exhibited increased striatal dopamine in late adolescence—a hallmark
molecular biomarker of schizophrenia. These results validate the MIA model in a species more closely related to
humans and open up new avenues for understanding the neurodevelopmental biology of schizophrenia and other
neurodevelopmental disorders associated with prenatal immune challenge.
Introduction
Mounting evidence from human epidemiological stu-
dies suggests that exposure to a variety of viral or bacterial
infections during pregnancy increases the risk for neu-
ropsychiatric and neurodevelopmental disorders in
exposed offspring1. The importance of the intrauterine
environment is further demonstrated by a series of recent
studies linking maternal inflammation during pregnancy,
as indexed by plasma interleukin 6 (IL-6) concentrations,
with offspring brain and behavior phenotypes relevant to
neurodevelopmental and neuropsychiatric disease2–5.
Animal model systems have established mechanistic links
between prenatal exposure to infection, the subsequent
maternal immune response and alterations in offspring
neurodevelopment6. One of the most widely used agents
in preclinical maternal immune activation (MIA) model
research is polyinosinic-polycytidylic acid (PolyIC), a
synthetic analog of double-stranded RNA, which triggers
a potent immune response7,8. Rodent offspring born to
PolyIC-injected dams exhibit changes in brain and beha-
vioral phenotypes that bear resemblance to human dis-
orders, including both autism spectrum disorder (ASD)
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and schizophrenia (SZ)9,10. The emerging consensus is
that activation of the maternal immune system during
pregnancy serves as a “disease primer” that, in combina-
tion with other genetic and/or environmental risk factors,
may increase the risk for specific neurodevelopmental
disorders11.
Although mouse models have laid the foundation for
evaluating the effects of prenatal immune challenge on
neurodevelopment, nonhuman primate models uniquely
facilitate exploration of complex social and cognitive
symptoms found in many human diseases12,13. The non-
human primate model closely resembles humans in both
behavior and neuroanatomical complexity and provides
an opportunity to bridge the gap between rodent model
systems and human patient populations14. Indeed, Coe
and colleagues have demonstrated that nonhuman pri-
mate offspring prenatally exposed to viral or bacterial
infections late in pregnancy exhibit alterations in brain
and behavioral development15,16. To further explore the
effects of the maternal immune response in the absence of
a specific pathogen, we developed the first PolyIC-based
nonhuman primate MIA model. Pregnant rhesus mon-
keys (Macaca mulatta) injected with a modified form of
PolyIC over three days at the end of either the first or
second trimester exhibited a transient but potent immune
response and produced offspring that developed abnor-
mal repetitive behaviors, reduced affiliative vocalizations,
and altered immune regulation17,18. As they matured, the
first trimester-exposed monkey offspring also exhibited
inappropriate interactions with novel conspecifics and
failed to attend to salient social cues in a highly transla-
tional eye-tracking paradigm19. The presence of abnormal
repetitive behaviors paired with alterations in social
development exhibited by MIA-treated offspring resemble
features of several neurodevelopmental disorders,
including both ASD and SZ.
Preclinical MIA models provide a unique opportunity to
explore the neurobiology of aberrant offspring behaviors
associated with maternal infection that may (or may not)
cross current human diagnostic categories20. Mice and
rats born to MIA-treated dams consistently show evi-
dence of aberrant dopamine system development,
including evidence of dopaminergic hyperfunction in the
striatum21–25. Given that increased striatal dopamine is
also a hallmark biological marker of SZ26, we initiated an
in vivo positron emission tomography (PET) study in
MIA-treated nonhuman primates to bridge the gap
between rodent MIA models and clinical populations.
MIA-treated and control animals were scanned at 3.5-
years of age using [18F] fluoro-l-m-tyrosine (FMT) to
measure presynaptic dopamine levels in the striatum.
Although sex differences are emerging as an important
factor in MIA model studies27 we had too few female
offspring in the original cohort and therefore limited this
initial PET pilot study to the 9 MIA-treated and 4 control
males. Here we present preliminary evidence indicating
that male nonhuman primate offspring born to MIA-
treated dams exhibited increased striatal dopamine in late
adolescence, thus extending findings from rodent MIA
models into a species more closely related to humans.
Methods
All experimental procedures were developed in colla-
boration with the veterinary, animal husbandry, and
environmental enrichment staff at the California National
Primate Research Center (CNPRC) and approved by the
University of California, Davis Institutional Animal Care
and Use Committee. All attempts were made (in terms of
social housing, enriched diet, use of positive reinforce-
ment strategies, and minimizing the duration of daily
training/testing sessions) to promote the psychological
well-being of the animals that participated in this
research. Detailed methods from this cohort are available
in our previous publications17,19 and have been updated
below to reflect newly developed MIA model reporting
guidelines8.
Subjects and maternal immune activation (MIA) protocol
The MIA offspring (Table 1) were born to dams injected
with 0.25 mg/kg synthetic double-stranded RNA (poly-
inosinic:polycytidylic acid [poly IC] stabilized with poly-L-
lysine [poly ICLC]; Oncovir, Inc., Washington, DC) via
intravenous (i.v.) injection while temporarily restrained by
trained technicians at the end of the first trimester on
gestational days (GD) 43, 44, 46 or at the end of the
second trimester on GD 100, 101, 103. CON offspring
were born to dams injected with saline at these same time
points, or had no manipulation at all during pregnancy.
Dams injected with poly ICLC exhibited a transient
increase in IL-6 levels, temperature and sickness beha-
viors as previously reported17. PET imaging studies
included all male control (CON; n= 4) and first trimester
MIA exposed (n= 5) and second trimester MIA exposed
(n= 4) offs.
Table 1 Experimental groups
Experimental group Original MIA cohort
(males, females)
PET imaging
(males only)
1st Trimester MIA (MIA1) n= 6 (5m, 1f) 5
2nd Trimester MIA
(MIA2)
n= 7 (4m, 3f) 4
Saline Controls n= 8 1st
Trimester (1m, 3f)
2nd Trimester (2m, 2f)
3
Untreated Controls n= 3 (1m, 2f) 1
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Rearing conditions and husbandry
All infants were born at term, raised with their mothers
and provided three hours daily access to a social group
consisting of four mother-infant pairs and one adult male
to facilitate species-typical social development. Infants
were raised in individual cages with their mothers where
they had visual access to other animals at all times. Infants
were weaned at 6-months of age, but continued daily peer
group interactions through approximately 2-years of age.
At the time of the current study, all animals were housed
indoors in social MIA/CON pairs 24 h per day, 7 days per
week. These pairs occupied two adjacent, age-appropriate
laboratory cages where they had visual access to other
animals. Animal rooms were maintained at 17.78–28.89 °C
and on a 12/12 light/dark cycle (lights on at 0600). Sub-
jects were fed twice daily (Lab Diet #5047, PMI Nutrition
International INC, Brentwood, MO), provided with fresh
produce biweekly, had access to water ad libitum and a
variety of enrichment devices.
Structural imaging
Structural MR imaging was performed prior to PET
imaging at the University of California Davis Imaging
Research Center using a 1.5 T GE Signa Horizon LX NV/I
MRI system (GE Medical Systems, Waukesha, WI, USA).
The protocol includes a T1-weighted SPGR (TR 27ms,
TE 6ms, Flip Angle 30, matrix 256×256, FOV 160mm,
slice thickness 0.7 mm).
Positron emission tomography (PET) imaging
Between 43.1 and 49.8 months of age, animals under-
went PET scans using 6-[18F]fluoro-L-m-tyrosine ([18F]
FMT). [18F]FMT was synthesized according to the
method of VanBrocklin et al.28 as follows. Cyclotron-
produced [18F]F2 (Siemens RDS111) was bubbled through
a solution of N,O-Di-Boc-2-TMSn-m-tyrosine ethyl ester
(ABX; 60mg) in Freon (15 mL) in a vented pyrex reaction
vessel at room temperature. The reaction mixture was
passed through 2070mg of silica gel in three cartridges
(Waters Sep Pak Plus). The protected intermediate pro-
duct was eluted from the cartridges in 25% diethyl ether/
hexane solution. Pooled high activity fractions (10 mL)
were added to 48% HBr (2 mL) and heated to 130 oC.
Ether/hexane was evaporated under a gentle stream of
nitrogen, after which hydrolysis in HBr was continued for
5 min. After cooling, the crude product solution was
partially neutralized in a solution of 50% w/w NaOH
(0.45 mL) and HPLC solvent (0.55 mL). [18F]FMT was
purified by HPLC, using a C18 column (Phenomenex
Luna, 10 × 250mm) eluted in 0.01% ascorbic acid/0.1%
acetic acid (aq) at 5 mL/min (tR 16–17min). HPLC-
purified [18F]FMT was formulated with 10% disodium
hydrogen phosphate (aq), 9% sodium chloride, and water
to prepare a neutral solution of desired volume in 0.9%
sodium chloride, then transferred with 0.22 µm filtration
to a dose vial. All preparations of [18F]FMT (n= 16)
demonstrated >99% radiochemical purity and >97%
enantiomeric purity, by analytical HPLC (Waters Breeze;
220 nm UV detection; inline Bioscan RA detection). For
radiochemical purity, [18F]FMT of measured activity was
injected onto a C18 column (Phenomenex Luna, 4.6 ×
250mm) and eluted in 5% ethanol (aq) at 0.4 mL/min.
Radiochemical purity was the fraction of total activity
associated with the [18F]FMT peak (tR 8.8 min). For
enantiomeric purity, [18F]FMT was co-injected with
authentic L-FMT and D-FMT standards (ABX) onto a
chiral column (Phenomenex Chirex D-penicillamine,
4.6 × 150mm) and eluted in 2mM copper (II) sulfate in
15% methanol (aq) at 1 mL/min (L-FMT tR= 22min; D-
FMT tRD= 29min). Animal weights were measured on
the day prior to the scan using the jump box method. On
the day of imaging, the animal was sedated using 10mg/kg
ketamine (IM), followed by placement of two indwelling IV
catheters into the cephalic and saphenous veins. The
cephalic vein is used for the carbidopa and radiotracer
injection while the saphenous vein is used for fluid therapy.
[18F]FMT behaves similarly to [18F]FDOPA and is meta-
bolized in the periphery, causing lower bio-availability in
the brain29. To avoid this metabolism, carbidopa was
administered as a peripheral decarboxylase inhibitor29–33.
For these studies, carbidopa (5 mg/kg) was injected
approximately 45 min prior to injection of [18F]FMT.
Heart rate, respiratory rate, and SPO2 were monitored
throughout the scan. Anesthetized animals were placed
on a custom-built bed for Rhesus Macaque and placed
headfirst into the microPET-P4 small animal PET scanner
(Siemens Preclinical Solutions, Knoxville TN). This
scanner has a reconstructed spatial resolution of
~2.0 mm34. First, a single pass transmission scan was
acquired from each animal as a reference for attenuation
and scatter corrections during image reconstruction. [18F]
FMT was administered at approximately 0.5 mCi/kg.
Once the radiotracer was injected, the IV catheter was
removed and any residual activity in the syringe was
measured. A 1.5 h dynamic emission scan was started
approximately 5 s prior to injection of the ligand. The
dynamic PET data consists of 24 frames of the following
durations: 10 frames at 1 min each, 5 frames at 2 min
each, 4 frames at 5 min each, and 5 frames at 10 min each.
Images were reconstructed using the 3DRP reconstruc-
tion algorithm with a Hann filter (cut-off at 0.3 Nyquist)
with attenuation and scatter correction applied. This
protocol has been extensively validated for quantitative
studies of the non-human primate brain.
Image analysis
Dynamic data was analyzed using PMOD (PMOD
Technologies Ltd., Zurich, Switzerland). A rough manual
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alignment of the PET images was performed before
automated registration. Dynamic PET [18F]FMT images
were registered to anatomical MRI images from each
animal. All PET frames were summed and a Gaussian
filter applied to smooth the data. The registration matrix
was saved and subsequently applied to the dynamic,
unsmoothed PET data. The Patlak reference tissue model
was used to determine an index of influx (Ki) of the
bilateral striatum for [18F]FMT studies using the cere-
bellum as the reference tissue35,36. For the Patlak analysis,
a time cutoff value of 25 min was used for model fitting to
provide the best sampling of dynamic data for linear fit-
ting of the model. All brain regions of interest were
defined on the co-registered MRI dataset by analysts blind
to the treatment condition of the animals. For [18F]FMT
Ki determination, bilateral caudate and putamen as
defined by refs. 37,38 were manually traced utilizing the
segmentation software ITK-snap39. No partial volume
corrections were performed as the resolution of the
striatum on the structural image in the NHP exceeded the
resolution of the PET scanner. However, we determined
that the tail of the caudate had insufficient resolution due
to size and was therefore anatomically delineated from the
head at its caudal extent and excluded from the manually
defined ROIs40. Statistical analyses were conducted using
IBM SPSS Statistics 25. Group differences in sample
characteristics, including age and weight (Table 2), were
tested with independent samples t-tests. In order to
account for variability in the Patlak reference tissue model
fit, group differences in FMT Ki were assessed using
weighted least squares regression, with the inverse of the
sum of squared residuals as weights. An estimate of the
effect size was calculated using Cohen’s d. Data approxi-
mated a normal distribution according to Shapiro–Wilk
tests (all p > 0.15). Additionally, data met criteria for equal
variances according to Levene’s Test (weight: p= 0.43,
age: p= 0.10, FMT Ki: p= 0.87).
Results
First trimester and second trimester MIA exposed males
were not significantly different in age (t(7)= 0.0238, p=
0.818), weight (t(7)= 0.113, p= 0.914), or [18F]FMT
index of influx (F1,7= 1.174, p= 0.314). Consequently, for
all analyses, all nine MIA exposed offspring were con-
sidered as one group, regardless of trimester of exposure.
MIA exposed offspring did not differ from control ani-
mals in weight (t(11)=1.051, p= 0.316), but were
approximately two months older on average (t(11)= 2.79,
p= 0.017) (Table 2). Analysis of [18F]FMT signal in the
striatum of these nonhuman primates showed that MIA
animals had significantly higher [18F]FMT index of influx
compared to control animals (F1,11= 10.98, p= 0.007)
(Fig. 1). In spite of the modest sample size, this group
difference reflects a large effect size (Cohen’s d= 0.998).
Discussion
The nonhuman primate model is uniquely positioned to
explore the confluence of prenatal immune challenge and
dopaminergic functioning in a highly translational animal
Table 2 Age, weight, and [18F] FMT for PET sample
Experimental
group
Age at scan in
years (SD)
Weight at scan in
kilograms (SD)
[18F]FMT index
of influx (SD)
MIA 3.95 (0.10) 7.50 (0.99) 0.0204 (0.0020)
Controls 3.75 (0.16) 6.82 (1.30) 0.0183 (0.0021)
Fig. 1 [18F]FMT index of influx in MIA-treated compared to control offspring. a Weighted least squares regression revealed that significantly
higher [18F]FMT index of influx in MIA compared to control animals (F1,11= 10.98, p= 0.007). b PET SUV images showing the striatal uptake of [
18F]
FMT. [18F]FMT PET images overlaid on anatomical MR images and are scaled to the same lower (0.5) and upper thresholds (1.5) as depicted in the
color bar
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model system. We have previously demonstrated that rhe-
sus monkeys exposed to prenatal immune challenge
develop aberrant behaviors after a period of early typical
development17–19. Here we present initial results from a
PET study carried out when these MIA-treated offspring
reached 3.5 years of age, which is roughly equivalent to late
adolescence in humans. Analysis of [18F]FMT signal in the
striatum of these nonhuman primates showed that MIA-
treated animals had significantly higher [18F]FMT index of
influx compared to control animals (Fig. 1). These data
provide the first evidence of hyperdopaminergia in a non-
human primate MIA model, which bridges the gap between
rodent MIA models and SZ patient populations.
Emerging evidence from rodent MIA models suggests that
dopaminergic alterations originating early in fetal develop-
ment contribute to the emergence of SZ-related behavioral
alterations observed as the offspring mature21. Rodent off-
spring born to MIA-treated dams exhibit a multitude of
behavioral alterations associated with dopamine system
functioning, including potentiation of amphetamine sensi-
tivity, disruption of selective attention, and sensorimotor
gating, that can be alleviated with dopamine-blocking
compounds25,41. Although we are at the early stages of
understanding the neurobiological basis of aberrant behavior
development in MIA-treated offspring, hyperdopaminergia
in the striatum has emerged as one of the more consistent
and translationally relevant outcomes. For example,
increased stimulated striatal dopamine release has been
observed in in vitro slice preparations derived from adult
rats born to dams injected with PolyI:C at mid/late gestation
(GD 15) compared to controls23. Increased dopamine
turnover has also been observed in the striatum of adult
mice born to dams that received multiple PolyI:C injections
from mid to late gestation (GD 12–17)24. Furthermore,
Meyer and colleagues have demonstrated increases in
dopamine-related neurochemical markers, such as tyrosine
hydroxylase (TH), in the striatum of adult mice born to
dams that received a single PolyI:C injection in early/mid
pregnancy (GD 9)42. Subsequent studies exploring age- and
region-specific dopaminergic alterations have reported an
initial decrease in TH immunoreactivity in peripubertal
MIA-treated mouse offspring that was followed by an
increase in TH immunoreactivity in the ventral (but not
dorsal) striatum when the mice reached adulthood22. Thus,
rodent MIA models have demonstrated abnormalities in
dopamine system development that are both region-specific
and dependent on the stage of offspring development.
Recent evidence suggests that co-administration of vitamin
D hormone during pregnancy prevents behavioral deficits43
and abnormal dopaminergic phenotypes44 in MIA-treated
offspring, possibly by exerting neuroprotective effects on the
developing dopamine system.
In spite of the mounting evidence of dopamine dys-
function in rodent MIA models, we are unaware of any
preclinical studies that have utilized PET imaging to
quantify striatal dopamine, as described below in human
patient populations. Thus, the present study extends the
rodent MIA model findings to a species more closely
related to humans and provides a novel model system to
further explore the role of aberrant dopaminergic devel-
opment following prenatal immune challenge. Interest-
ingly, abnormalities in dopamine system development
described in MIA-treated nonhuman primates aligns with
previous behavioral observations from this same cohort.
In an exploratory eye-tracking study, we reported that the
first trimester MIA-exposed nonhuman primates failed to
attend to salient social features (i.e., the eye region) in a
species-typical manner19. Given that the mesolimbic
dopamine system and the cortical salience network are
thought to play a critical role in the detection of beha-
viorally relevant environmental stimuli45, it is plausible
that early disturbances in dopaminergic development may
alter salience processing abilities. Indeed, aberrant func-
tioning of both the salience network and the mesolimbic
dopamine have been observed in numerous neu-
ropsychiatric disorders, including disorders associated
with maternal infection, such as SZ46–49.
Translationally aligned with our findings, two recent
meta-analyses of molecular imaging studies in human
patients report elevated striatal dopamine in SZ50,51. Pre-
vious studies in individuals with SZ suggest that the striatal
"hyperdopaminergic" state in the illness is primarily driven
by presynaptic (e.g., increased DA synthesis) as opposed to
postsynaptic (e.g., increased postsynaptic DA receptor
expression) mechanisms52–59. Although the precise ana-
tomical locus of dopamine dysfunction within the striatum
remains unclear, a recent meta-analysis suggests that
dopaminergic dysfunction is greater in dorsal compared to
limbic subdivisions of the striatum for patients with SZ60.
Elevated presynaptic dopamine has also been observed in
at-risk subjects61 and is correlated with prodromal symp-
tom severity and furthermore may predict transition to
psychosis in at-risk patients62. The potential clinical utility
of presynaptic dopamine as a molecular biomarker for
psychosis has also been demonstrated in PET studies
comparing treatment responders and non-responders.
Specifically, striatal dopamine levels have been shown to
predict antipsychotic treatment response in SZ, with
striatal dopamine synthesis capacity elevated in treatment
responders but not in non-responders63,64. Presynaptic
dopamine, therefore, may be used to identify patients
unlikely to respond to antipsychotic treatment and who
therefore may require alternative or additional forms of
treatment. Recent studies have also begun to explore the
association between childhood adversity (e.g., abuse,
multiple families, immigration), elevated striatal dopamine
function and increased risk of developing psychosis65,66.
Although additional research is needed to understand the
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complex relationship between early life stress and dopa-
mine dysregulation67, the MIA model is uniquely posi-
tioned to address these questions by incorporating second
“hits” such as postnatal stress following prenatal immune
challenge68.
Taken together with the present findings, these results
support striatal presynaptic hyperdopaminergia as a
clinically relevant, translational target biomarker for SZ
patients and at-risk populations. The present study con-
tributes to mounting evidence implicating dopamine
dysregulation as a potential mechanism underlying
behavioral abnormalities induced by prenatal immune
challenge. The primary limitation of the current study is
the small sample size of MIA-treated nonhuman pri-
mates. Given that early translational studies tend to have
quite high per-subject costs, initial nonhuman primate
studies must balance the potential information gained
versus ethical and financial factors69. Thus, small sample
sizes are not uncommon for initial pilot studies in non-
human primates70–73. Moreover, the current study
included only male subjects prenatally exposed to MIA,
thus we are unable to explore sex differences that have
been reported in previous rodent MIA models41. Despite
these limitations, this initial nonhuman primate PET
study extends the findings of dopamine dysregulation in
rodent MIA models to a species more closely related to
humans, thereby highlighting clinical relevance of the
nonhuman primate MIA model for understanding the
neurodevelopmental origins of SZ. In future studies, we
will take advantage of the unique opportunities provided
by this nonhuman primate neurodevelopmental model of
psychosis risk to study brain structure, function and
chemistry longitudinally, along with more sophisticated
cognitive and social behavioral phenotyping, in a new
cohort of MIA nonhuman primates. This approach has
the potential to identify the relationship between emer-
ging adolescent behavioral disturbances and hyperdopa-
minergia and to identify changes in brain structure and
function and optimiz their measurement in order to
provide biomarkers for risk prediction for future long-
itudinal studies of young people at risk for psychosis.
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